Can a drug combo shield lungs from radiation damage?
NCT ID NCT06634056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this reduces side effects and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pentoxifylline and vitamin E (α-tocopherol)
What this could lead to
If it works, this could reduce the risk of radiation-induced lung injury and improve quality of life for lung cancer patients.
What could go wrong
This is a Phase 2 trial with 150 participants, so results are still early. The drugs may not prevent lung injury, and side effects from the combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact